Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

UncleTomFlorida Feb. 9 at 8:00 AM

$ABCL is a biotech company which uses its own AI. Vertically integrated, saving $7.5 Million a year on real estate expense, with # of successful antibodies possibly compounding exponentially, infinite TAM, Patent moat, backed by govts and zero debt. I buy several shares a week w/loose change. Expecting 10x return over 3 yrs. This company will turn the thrifty into millionaires.

0 · Reply

RobbieBaker1010 Feb. 9 at 7:30 AM

$ABCL platform potential supports upside, though monetization remains early.

0 · Reply

Biotechsleuth Feb. 8 at 8:10 PM

$ABCL

0 · Reply

UgoGreg Feb. 8 at 5:55 PM

$ABCL https://youtu.be/ygBN8MilTyc

0 · Reply

UgoGreg Feb. 8 at 4:28 PM

$ABCL https://youtu.be/b4CDDEB3OQo

0 · Reply

EchoAnalysis8 Feb. 8 at 4:13 PM

$ABCL — has likely bottomed Price tested the 0.786 Fib and reacted well, up +13%. I want to see price flip the 50-WMA to support before I buy. Wave 5 → +363%

0 · Reply

JennyRowes Feb. 7 at 2:23 PM

$ABCL could this be the next Regeneron in the making? “AbCellera Biologics is increasingly being valued as a struggling biotech rather than a scaled antibody discovery platform with expanding clinical optionality. The progression of ABCL635 into Phase 2, combined with analyst confidence and upcoming financial disclosures, suggests that the market may be mispricing both execution capability and long-term growth potential. For investors seeking exposure to platform-driven biotech upside at a depressed valuation, ABCL offers a compelling risk-reward profile under $5.”

2 · Reply

PorkchopSquats Feb. 7 at 1:44 PM

$ABCL Follow me for more would’ve/should’ve calls that I’m too much of a bitch to do myself.

0 · Reply

Samb2344 Feb. 7 at 12:16 AM

$ABCL any buys

0 · Reply

Odoji Feb. 6 at 7:45 PM

$ABCL 💉

0 · Reply

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 9:16 PM EST - 25 days ago

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 9:00 AM EST - 4 weeks ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 7 weeks ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 2 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 1:37 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 22, 2025, 12:23 AM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 9:00 AM EST - 3 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 3 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 4 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 5 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 5 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 6 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 9 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 9 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 9 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 9 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 9 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 10 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 11 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

UncleTomFlorida Feb. 9 at 8:00 AM

0 · Reply

RobbieBaker1010 Feb. 9 at 7:30 AM

$ABCL platform potential supports upside, though monetization remains early.

0 · Reply

Biotechsleuth Feb. 8 at 8:10 PM

$ABCL

0 · Reply

UgoGreg Feb. 8 at 5:55 PM

$ABCL https://youtu.be/ygBN8MilTyc

0 · Reply

UgoGreg Feb. 8 at 4:28 PM

$ABCL https://youtu.be/b4CDDEB3OQo

0 · Reply

EchoAnalysis8 Feb. 8 at 4:13 PM

$ABCL — has likely bottomed Price tested the 0.786 Fib and reacted well, up +13%. I want to see price flip the 50-WMA to support before I buy. Wave 5 → +363%

0 · Reply

JennyRowes Feb. 7 at 2:23 PM

2 · Reply

PorkchopSquats Feb. 7 at 1:44 PM

$ABCL Follow me for more would’ve/should’ve calls that I’m too much of a bitch to do myself.

0 · Reply

Samb2344 Feb. 7 at 12:16 AM

$ABCL any buys

0 · Reply

Odoji Feb. 6 at 7:45 PM

$ABCL 💉

0 · Reply

LIVE_Trading Feb. 6 at 6:42 PM

$ABCL watch here. Near to High.

0 · Reply

LIVE_Trading Feb. 6 at 6:31 PM

Currently holding $ABCL $ABAT $AIRS $GDRX $$GERN

0 · Reply

LIVE_Trading Feb. 6 at 6:15 PM

bought $ABCL $SPY

0 · Reply

tkstockpicker Feb. 6 at 4:40 PM

$ABCL Next 🎯 3.33

0 · Reply

DeMampCamp Feb. 6 at 3:54 PM

$ABCL Welcome back 3s, now fight like hell to protect it! Congratulations to anyone that picked up shares in the 2s, being completely transparent, I didn't pick up a single share, I need to see a new confirmed bottom before I do, been burned way too many times!

3 · Reply

tkstockpicker Feb. 6 at 3:18 PM

$ABCL bought

0 · Reply

Brb579 Feb. 6 at 1:58 PM

$ABCL its over bro.

0 · Reply

DeMampCamp Feb. 6 at 1:40 PM

$ABCL Be very careful here, we know how this ALWAYS dives at the open and I most certainly don't trust this overall green market this morning, I won't be surprised whatsoever to see investors taking immediate profits at the bell. It sure would be a great morale booster to get back into the 3s though! Happy Friday everyone!

0 · Reply

BioTechHealthX Feb. 6 at 11:30 AM

$ABCL Despite trading at depressed levels, AbCellera Biologics continues to earn Buy ratings from analysts. This article explores why NASDAQ: ABCL’s platform, pipeline progress, and upcoming earnings could challenge the market’s pessimism.https://biotechhealthx.com/biotech-news/heres-why-wall-street-still-says-buy-even-as-abcellera-abcl-trades-like-a-penny-stock/

1 · Reply

Odoji Feb. 6 at 11:22 AM

$ABCL

0 · Reply

BioTechHealthX Feb. 6 at 10:53 AM

$DNA $AEMD $ABCL $SXTC $THAR Biotech stocks often surge on news tied to clinical progress and regulatory updates. Learn why breakthroughs in drug discovery, genetics, and AI are translating into rapid price action across the sector today. https://biotechhealthx.com/biotech-news/top-10-biotech-stocks-with-the-biggest-price-gains-today/

0 · Reply

Odoji Feb. 6 at 10:29 AM

$ABCL 💉

1 · Reply

Market Cap	945.90M
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	2,520,182
Avg Vol	4,369,448
Day's Range	N/A - N/A
Shares Out	299.34M
Stochastic %K	28%
Beta	0.81
Analysts	Strong Sell
Price Target	$9.00